[1]
Tan ML, Choong PF, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2009; 61(1): 3-12.
Google Scholar
[2]
Tan ML, Choong PF, Dass CR. Doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol. 2009; 61(2): 131-42.
Google Scholar
[3]
Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracyclineinduced clinical heart failure in children: a systematic review. Ann Oncol 2002; 13(4): 503-12.
DOI: 10.1093/annonc/mdf118
Google Scholar
[4]
Longhi A, Ferrari S, Bacci G, Specchia S. Long-term follow-up of patients with doxorubicininduced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs 2007; 18(6): 737-44.
DOI: 10.1097/cad.0b013e32803d36fe
Google Scholar
[5]
Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32(6): 423-36.
DOI: 10.1016/j.ctrv.2006.05.005
Google Scholar
[6]
Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextrandoxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001; 74(13): 317-23.
DOI: 10.1016/s0168-3659(01)00342-x
Google Scholar
[7]
Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis. 2006; 23(7-8): 367-80.
DOI: 10.1007/s10585-006-9046-6
Google Scholar
[8]
Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res. 1993 15; 53(20): 4890-5.
Google Scholar